
Sign up to save your podcasts
Or
Stocks ending the day near their highs of the session with the Nasdaq notching its first record close since November 2021. But in a month that saw broad strength in the market, a couple names really stood out. Do you stick with the big winners into March? Or will some of this month’s laggards gain some spring in their step? Plus, unapproved copycat versions of obesity drugs could throw a wrench in the red-hot market. The impact on users, and the stocks tipping the scales in the weight loss wars.
Fast Money Disclaimer
3.9
12371,237 ratings
Stocks ending the day near their highs of the session with the Nasdaq notching its first record close since November 2021. But in a month that saw broad strength in the market, a couple names really stood out. Do you stick with the big winners into March? Or will some of this month’s laggards gain some spring in their step? Plus, unapproved copycat versions of obesity drugs could throw a wrench in the red-hot market. The impact on users, and the stocks tipping the scales in the weight loss wars.
Fast Money Disclaimer
4,074 Listeners
239 Listeners
3,178 Listeners
147 Listeners
327 Listeners
67 Listeners
153 Listeners
2,139 Listeners
2,075 Listeners
601 Listeners
546 Listeners
20 Listeners
1,542 Listeners
200 Listeners
407 Listeners
302 Listeners
115 Listeners
805 Listeners
181 Listeners
60 Listeners
156 Listeners
22 Listeners
34 Listeners
15 Listeners
9 Listeners
276 Listeners
15 Listeners